Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.

Also called NCT03604419

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 214 participants (enrolled count) (from the registry)
Sponsor
  • Covance Registry lists this organization as a collaborator
  • PegBio Co., Ltd. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03604419
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03604419. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-13 (actual); primary completion 2019-07-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
PB-119 100 μg+ Glucophage®
Intervention (Drug)
PB-119 150 μg+ Glucophage®
Intervention (Drug)
PB-119 200 μg+ Glucophage®
Intervention (Drug)
PB-119 placebo + Glucophage®
Lead sponsor
PegBio Co., Ltd. (class: other)
Collaborator
Covance (class: industry)

Record details

Record id
cardio:ct-nct03604419
Content hash
bd1bdaf1236cf77b089be465d4d869593c2bf92f0a3ae3d72d04d96eec469e99